Mario was involved in the creation of Alethia in 2002. In his current position, he oversees Alethia’s operations including research and development, pre-clinical studies, collaborations with Universities . Prior, he acted as President of the Clinical Genomics Unit at SignalGene. Prior to joining SignalGene, Mario served as Director, Biotechnology at T2C2/Bio, a leading venture capital fund in Montréal. Earlier in his career, he acted as Director, Molecular Genetics of Algène Biotechnologies. Mario holds a Ph.D. degree in molecular biology from l’Université de Montréal and was an NSERC and FRSQ post-doctoral fellow at McGill University.

Dr. Jolivet brings to Alethia over 25 years of expertise as both a corporate executive as well as a practicing clinical oncologist. Prior to joining Alethia, Dr. Jolivet served as Senior Vice-President, Clinical Development at Aegera Therapeutics. Previously, he served as Director of Clinical Development, Oncology at Shire Pharmaceuticals and its predecessor, BioChem Pharma, where he played a key role in the development of Troxatyl. Dr. Jolivet maintains a clinical oncology practice at the Hematology and Medical Oncology department of the Hôtel Dieu Hospital of St.-Jerôme. Dr. Jolivet received his medical degree from l’Universite de Montreal, and completed his residency in internal medicine at the Royal Victoria Hospital. He completed a 3-year fellowship in anticancer drug pharmacology at the National Cancer Institute in Besthesda, MD. Dr. Jolivet led a research laboratory at the University of Montreal for 15 years, and has received numerous grants and awards for his research culminating in two issued US patents and more than 80 published papers.

Julie is overseeing the clinical programs of Alethia Biotherapeutics’ lead candidates. She has more than 25 years of experience in the pharmaceutical industry with extensive experience in preclinical and clinical development projects. Prior to joining Alethia Biotherapeutics, she held various progressive positions at BELLUS Health/Neurochem Inc. during a 14-year period to Director of Preclinical Research and Clinical Research. Julie is a pharmacist and holds a Ph.D. in Pharmaceutical Sciences from the Université de Montréal with a focus in pharmacokinetic and pharmacodynamic modeling.